BioCentury | Nov 19, 2019
Company News

Nov. 18 Company Quick Takes: Eidos spikes on latest amyloidosis readout; plus Janssen, Pfizer, Tricida, BMS-Celgene

...outstanding shares this year, added $0.81 to $29.07. Janssen, PRA launch digital clinical trial of Invokana...
...Sciences Inc. (NASDAQ:PRAH) launched CHIEF-HF, a digital clinical trial using wearable devices to evaluate Invokana canagliflozin...
...Celgene's $13.4B sale of Otezla, Amgen adds to anti-inflammatory franchise" ). BioCentury Staff Canaglu, Invokana, canagliflozin (JNJ-28431754, TA-7284) Humira...
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

...kidney function decline measured by eGFR. The other came on Monday, when FDA approved Invokana canagliflozin...
...addressing nephritic syndromes. Today, there are over 25. That’s a tremendous surge.” Karen Cashmere, ZyVersa “Invokana...
BioCentury | Jul 10, 2019
Politics & Policy

CMS’s new CKD payment models could be mixed bag for drug companies

...are cropping up that could give these physicians a tool to achieve that goal. Invokana canagliflozin...
...renal or cardiovascular death (p<0.0001). Invokana reduced the risk of ESRD by 32% (see " Invokana...
...diabetes and CKD. A PDUFA date was not disclosed. Erin McCallister, Senior Editor Canaglu, Invokana, canagliflozin (JNJ-28431754, TA-7284) Centers...
BioCentury | May 22, 2019
Company News

May 22 Company Quick Takes: Lilly adds warning to Verzenio's Japanese label; plus Janssen, a pair of China approvals and more

...Humalog's WAC is $274.70 (see "Lilly Offers Cheaper Insulin, Pressuring Competitors" ). Priority Review for Invokana...
...FDA accepted and granted Priority Review to an sNDA from Janssen Pharmaceuticals Inc. for Invokana canagliflozin...
...in August 2022 and cost ¥127.3 billion ($1.2 billion). Elizabeth Eaton, Staff Writer Canaglu, Invokana, canagliflozin (JNJ-28431754, TA-7284) Shingrix...
BioCentury | May 8, 2019
Company News

Gilead’s Goldfinch deal signals renewed optimism in kidney therapies

...Johnson (NYSE:JNJ) unit Janssen that it submitted an sNDA to FDA for diabetes drug Invokana canagliflozin...
...disease in Type II diabetics. Janssen presented the supporting Phase III data last month (see "Invokana...
BioCentury | Apr 15, 2019
Clinical News

Invokana reduces composite endpoint by 30% in Type II diabetics with CKD

...efficacy in the indication. The latest is Invokana canagliflozin from Janssen, which said Sunday that Invokana...
...angiotensin II receptor blockers (ARBs), in combination with placebo or once-daily 100 mg oral Invokana. Invokana...
...Hypoxia-inducible factor prolyl hydroxylase; SGLT2 - Sodium-glucose cotransporter 2 Brian Moy, Assistant Editor Canaglu, Invokana, canagliflozin (JNJ-28431754, TA-7284) Johnson...
BioCentury | Nov 16, 2018
Clinical News

AZ’s Farxiga reduces heart failure, but misses on CV events

...in Chicago showed the sodium-glucose cotransporter 2 (SGLT2) inhibitor lagging behind Jardiance empagliflozin and Invokana canagliflozin...
...exercise to improve glycemic control in adults with Type II diabetes. SGLT2 inhibitors Jardiance and Invokana...
...greater reductions in hospitalizations due to heart failure, with Jardiance showing a 35% reduction and Invokana...
BioCentury | Nov 12, 2018
Clinical News

AZ’s Farxiga reduces heart failure, but misses on CV events

...in Chicago showed the sodium-glucose cotransporter 2 (SGLT2) inhibitor lagging behind Jardiance empagliflozin and Invokana canagliflozin...
...exercise to improve glycemic control in adults with Type II diabetes. SGLT2 inhibitors Jardiance and Invokana...
...greater reductions in hospitalizations due to heart failure, with Jardiance showing a 35% reduction and Invokana...
BioCentury | Nov 9, 2018
Product Development

Cashing out CVOT

...in time to first occurrence of MACEs in CVOTs: SGLT2 inhibitors Jardiance empagliflozin and Invokana canagliflozin...
...Victoza liraglutide. Jardiance is marketed by partners Boehringer Ingelheim GmbH and Eli Lilly and Co., Invokana...
BioCentury | Nov 2, 2018
Clinical News

FDA approves Janssen's Invokana to reduce MACE in Type II diabetics

...Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said FDA approved an sNDA for Invokana canagliflozin...
...factors (see “J&J’s Invokana Improves CV Outcomes Despite Amputation Risk” ). J&J has rights to Invokana...
...New Brunswick, N.J. Product: Invokana canagliflozin (JNJ-28431754, TA-7284) Business: Endocrine/Metabolic Jaime De Leon Canaglu, Invokana, canagliflozin (JNJ-28431754, TA-7284) Johnson...
Items per page:
1 - 10 of 110